Difference between revisions of "Part:BBa K4905010"
VeerleJegers (Talk | contribs) |
VeerleJegers (Talk | contribs) |
||
Line 6: | Line 6: | ||
<h1>Information</h1> | <h1>Information</h1> | ||
<p> | <p> | ||
− | This part is made up of the basic parts: two times Elastin-Like Polypeptide (ELP) sequence A[60]I[60] (<a href="https://parts.igem.org/Part:BBa_K4905001">BBa_K4905001</a>) and two times FKBP12 (<a href="https://parts.igem.org/Part:BBa_K3610022">BBa_K3610022</a>). This results in the sequence FKBP12-I[60]-A[120]-I[60]-FKBP12. With A the sequence (VPGAG | + | This part is made up of the basic parts: two times Elastin-Like Polypeptide (ELP) sequence A[60]I[60] (<a href="https://parts.igem.org/Part:BBa_K4905001">BBa_K4905001</a>) and two times FKBP12 (<a href="https://parts.igem.org/Part:BBa_K3610022">BBa_K3610022</a>). This results in the sequence FKBP12-I[60]-A[120]-I[60]-FKBP12. With A[5] the sequence (VPGAG[3]VPGGG[2]), since there are five VPGXG repeats, and I the sequence (VPGIG). The numbers indicate the number of repeats of these sequences. This construct was used by the TU Eindhoven 2023 team to form a hydrogel outside as well as inside <i>E.coli</i> BL21 cells. A schematic overview of this is shown in figure 1. |
</p> | </p> | ||
− | <figure><img src="https://static.igem.wiki/teams/4905/wiki/partsconstructs/partsconstructs/ | + | <figure><img src="https://static.igem.wiki/teams/4905/wiki/partsconstructs/partsconstructs/part10nieuw.png" width="640px"> |
<figcaption> | <figcaption> | ||
− | <p><b>Figure 1 | </b>Schematic overview of the sequence of this construct. VPGAG | + | <p><b>Figure 1 | </b>Schematic overview of the sequence of this construct. (VPGAG[3]VPGGG[2]) is from now on referred to as A[5] and VPGIG is referred to as I. </p> |
</figcaption> | </figcaption> | ||
</figure><be> | </figure><be> |
Revision as of 09:47, 22 September 2023
Elastin-Like Polypeptide Triblock with FKBP12
Information
This part is made up of the basic parts: two times Elastin-Like Polypeptide (ELP) sequence A[60]I[60] (BBa_K4905001) and two times FKBP12 (BBa_K3610022). This results in the sequence FKBP12-I[60]-A[120]-I[60]-FKBP12. With A[5] the sequence (VPGAG[3]VPGGG[2]), since there are five VPGXG repeats, and I the sequence (VPGIG). The numbers indicate the number of repeats of these sequences. This construct was used by the TU Eindhoven 2023 team to form a hydrogel outside as well as inside E.coli BL21 cells. A schematic overview of this is shown in figure 1.
General applications
ELPs are protein polymers derived from human tropoelastin. One of their key features is that they exhibit a phase separation that is often reversible whereby samples remain soluble below Tt but form coacervates above Tt. They have many possible applications in purification, sensing, activation, and nano assembly. Furthermore, they are non-immunogenic, substrates for proteolytic biodegradation, and can be decorated with pharmacologically active peptides, proteins, and small molecules. Recombinant synthesis additionally allows precise control over ELP architecture and molecular weight, resulting in protein polymers with uniform physicochemical properties suited to the design of multifunctional biologics. As such, ELPs have been employed for various uses including as anti-cancer agents, ocular drug delivery vehicles, and protein trafficking modulators3.
Construct design
The construct consists of ELPs and FKBP12. In general, ELPs have hydrophilic and hydrophobic domains that exhibit reversible phase separation behavior that is temperature-dependent. They are made from a repeating VPGXG sequence, with X replaced by specific amino acids. This results in specific properties of the ELPs, especially related to the transition temperature Tt at which the ELPs will interact with each other on the hydrophobic sites2. When the temperature is below Tt, the water molecules surrounding the hydrophobic parts will go into the bulk water phase which gains the solvent entropy. This makes it possible to form interactions with other ELP molecules3.
This construct has a hydrophilic region in the middle (A[120]) and a hydrophobic region on each side of it (I[60]). On the ends, FKBP12 domains are located for stronger interactions between the ELPs. FKBP12 can form a complex with Rapamycin and the FKBP-rapamycin binding (FRB) domain. This mechanism is normally used in the mTOR pathway inside cells, which regulates cellular proliferation, protein synthesis, differentiation and survival, and lipid metabolism. In the case of a hydrogel, the addition of rapamycin to a cell with these ELPs and ELPs with FRB at the ends can induce crosslinking between them to form a network (bron inobe en yandong liu). These stronger interactions make them useful in the formation of a hydrogel.
As soon as the hydrogel is made inside E.coli BL21 cells, the cells are prevented from dividing. However, the cells remain functional. So they can still be used to express therapeutic agents, like Interleukin 10 in the TU Eindhoven 2023 teams project.
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal EcoRI site found at 2222
Illegal EcoRI site found at 4148
Illegal XbaI site found at 339
Illegal XbaI site found at 2265 - 12INCOMPATIBLE WITH RFC[12]Illegal EcoRI site found at 2222
Illegal EcoRI site found at 4148 - 21INCOMPATIBLE WITH RFC[21]Illegal EcoRI site found at 2222
Illegal EcoRI site found at 4148
Illegal XhoI site found at 2239
Illegal XhoI site found at 4165 - 23INCOMPATIBLE WITH RFC[23]Illegal EcoRI site found at 2222
Illegal EcoRI site found at 4148
Illegal XbaI site found at 339
Illegal XbaI site found at 2265 - 25INCOMPATIBLE WITH RFC[25]Illegal EcoRI site found at 2222
Illegal EcoRI site found at 4148
Illegal XbaI site found at 339
Illegal XbaI site found at 2265
Illegal NgoMIV site found at 396
Illegal NgoMIV site found at 576
Illegal NgoMIV site found at 666
Illegal NgoMIV site found at 846
Illegal NgoMIV site found at 2322
Illegal NgoMIV site found at 2502
Illegal NgoMIV site found at 2592 - 1000COMPATIBLE WITH RFC[1000]
Results
References